The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence

Overview

Journal Alcohol Clin Exp Res

Specialty Psychiatry

Date 2017 Apr 20

PMID 28421616

Citations 5

Authors

Breanne Hobden

Melanie L Schwandt

Mariko Carey

Mary R Lee

Mehdi Farokhnia

Sofia Bouhlal

Christopher Oldmeadow

Lorenzo Leggio

Affiliations

Soon will be listed here.

Abstract

Background: The Montgomery-Asberg Depression Rating Scale (MADRS) is commonly used to examine depressive symptoms in clinical settings, including facilities treating patients for alcohol addiction. No studies have examined the validity of the MADRS compared to an established clinical diagnostic tool of depression in this population. This study aimed to examine the following: (i) the validity of the MADRS compared to a clinical diagnosis of a depressive disorder (using the Structured Clinical Interview for DSM-IV-TR [SCID-IV-TR]) in patients seeking treatment for alcohol dependence (AD); (ii) whether the validity of the MADRS differs by type of SCID-IV-TR-based diagnosis of depression; and (iii) which items contribute to the optimal predictive model of the MADRS compared to a SCID-IV-TR diagnosis of a depressive disorder.

Methods: Individuals seeking treatment for AD and admitted to an inpatient unit were administered the MADRS at day 2 of their detoxification program. Clinical diagnoses of AD and depression were made via the SCID-IV-TR at the beginning of treatment.

Results: In total, 803 participants were included in the study. The MADRS demonstrated low overall accuracy relative to the clinical diagnosis of depression with an area under the receiver operating characteristic curve of 0.68. The optimal threshold for balancing sensitivity and specificity identified by the Euclidean distance was >14. This cut-point demonstrated a sensitivity of 66%, a specificity of 60%, a positive predictive value of 50%, and a negative predictive value of 75%. The MADRS performed slightly better for major depressive disorders compared to alcohol-induced depression. Items related to lassitude, concentration, and appetite slightly decreased the accuracy of the MADRS.

Conclusions: The MADRS does not appear to be an appropriate substitute for a diagnostic tool among alcohol-dependent patients. The MADRS may, however, still be a useful screening tool assuming careful consideration of cut-points.

Citing Articles

Evolution of Cognitive Impairments in Treatment-Resistant Depression: Results from the Longitudinal French Centers of Expertise for Treatment-Resistant Depression (FACE-DR) Cohort.

Vancappel A, Dansou Y, Godin O, Haffen E, Yrondi A, Stephan F Brain Sci. 2023; 13(7).

PMID: 37509050 PMC: 10377578. DOI: 10.3390/brainsci13071120.

Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine.

Machavariani E, Bromberg D, Dumchev K, Dvoriak S, Zeziulin O, Morozova O Contemp Clin Trials. 2023; 131:107248.

PMID: 37263492 PMC: 10527419. DOI: 10.1016/j.cct.2023.107248.

Receiver operating characteristic curve: overview and practical use for clinicians.

Nahm F Korean J Anesthesiol. 2022; 75(1):25-36.

PMID: 35124947 PMC: 8831439. DOI: 10.4097/kja.21209.

Non-pharmacological treatment of gambling disorder: a systematic review of randomized controlled trials.

Ribeiro E, Afonso N, Morgado P BMC Psychiatry. 2021; 21(1):105.

PMID: 33596853 PMC: 7888125. DOI: 10.1186/s12888-021-03097-2.

Mechanism and therapeutic strategies of depression after myocardial infarction.

Yang Y, Li X, Chen S, Xiao M, Liu Z, Li J Psychopharmacology (Berl). 2021; 238(6):1401-1415.

PMID: 33594503 DOI: 10.1007/s00213-021-05784-0.

References

Leentjens A, Verhey F, Lousberg R, Spitsbergen H, Wilmink F . The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry. 2000; 15(7):644-9. DOI: 10.1002/1099-1166(200007)15:7<644::aid-gps167>3.0.co;2-l. View

Muller M, Szegedi A, WETZEL H, Benkert O . Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale. J Affect Disord. 2000; 60(2):137-40. DOI: 10.1016/s0165-0327(99)00162-7. View

Hawley C, Gale T, Sivakumaran T . Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002; 72(2):177-84. DOI: 10.1016/s0165-0327(01)00451-7. View

Muller M, Himmerich H, Kienzle B, Szegedi A . Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord. 2003; 77(3):255-60. DOI: 10.1016/s0165-0327(02)00120-9. View

Gual A, Balcells M, Torres M, Madrigal M, Diez T, Serrano L . Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol. 2003; 38(6):619-25. DOI: 10.1093/alcalc/agg124. View

Henkel V, Mergl R, Kohnen R, Allgaier A, Moller H, Hegerl U . Use of brief depression screening tools in primary care: consideration of heterogeneity in performance in different patient groups. Gen Hosp Psychiatry. 2004; 26(3):190-8. DOI: 10.1016/j.genhosppsych.2004.02.003. View

Pettinati H . Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry. 2004; 56(10):785-92. DOI: 10.1016/j.biopsych.2004.07.016. View

Sullivan L, Fiellin D, OConnor P . The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med. 2005; 118(4):330-41. DOI: 10.1016/j.amjmed.2005.01.007. View

Burns L, Teesson M, ONeill K . The impact of comorbid anxiety and depression on alcohol treatment outcomes. Addiction. 2005; 100(6):787-96. DOI: 10.1111/j.1360-0443.2005.001069.x. View

10.

Dongier M . What are the treatment options for comorbid alcohol abuse and depressive disorders?. J Psychiatry Neurosci. 2005; 30(3):224. PMC: 1089782. View

11.

Conway K, Compton W, Stinson F, Grant B . Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006; 67(2):247-57. DOI: 10.4088/jcp.v67n0211. View

12.

Cairney J, Veldhuizen S, Wade T, Kurdyak P, Streiner D . Evaluation of 2 measures of psychological distress as screeners for depression in the general population. Can J Psychiatry. 2007; 52(2):111-20. DOI: 10.1177/070674370705200209. View

13.

Dum M, Pickren J, Sobell L, Sobell M . Comparing the BDI-II and the PHQ-9 with outpatient substance abusers. Addict Behav. 2007; 33(2):381-7. DOI: 10.1016/j.addbeh.2007.09.017. View

14.

Kodl M, Fu S, Willenbring M, Gravely A, Nelson D, Joseph A . The impact of depressive symptoms on alcohol and cigarette consumption following treatment for alcohol and nicotine dependence. Alcohol Clin Exp Res. 2007; 32(1):92-9. DOI: 10.1111/j.1530-0277.2007.00556.x. View

15.

Williams J, Kobak K . Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008; 192(1):52-8. DOI: 10.1192/bjp.bp.106.032532. View

16.

Muhonen L, Lonnqvist J, Juva K, Alho H . Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008; 69(3):392-9. DOI: 10.4088/jcp.v69n0308. View

17.

McPherson A, Martin C . A narrative review of the Beck Depression Inventory (BDI) and implications for its use in an alcohol-dependent population. J Psychiatr Ment Health Nurs. 2010; 17(1):19-30. DOI: 10.1111/j.1365-2850.2009.01469.x. View

18.

Pettinati H, Oslin D, Kampman K, Dundon W, Xie H, Gallis T . A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010; 167(6):668-75. PMC: 3121313. DOI: 10.1176/appi.ajp.2009.08060852. View

19.

Muhonen L, Lahti J, Alho H, Lonnqvist J, Haukka J, Saarikoski S . Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence. Psychiatry Res. 2010; 186(1):53-7. DOI: 10.1016/j.psychres.2010.07.039. View

20.

Gjerdingen D, McGovern P, Center B . Problems with a diagnostic depression interview in a postpartum depression trial. J Am Board Fam Med. 2011; 24(2):187-93. PMC: 3097469. DOI: 10.3122/jabfm.2011.02.100197. View